Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a potential biomarker and therapeutic target

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/95a48b4cc3c74d05b739c67d702815e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:95a48b4cc3c74d05b739c67d702815e2
record_format	dspace
spelling	oai:doaj.org-article:95a48b4cc3c74d05b739c67d702815e22021-12-02T15:35:55ZSelective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML10.1038/s41467-019-11413-42041-1723https://doaj.org/article/95a48b4cc3c74d05b739c67d702815e22019-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11413-4https://doaj.org/toc/2041-1723In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a potential biomarker and therapeutic targetThomas OellerichConstanze SchneiderDominique ThomasKirsten M. KnechtOlga BuzovetskyLars KaderaliChristoph SchliemannHanibal BohnenbergerLinus AngenendtWolfgang HartmannEva WardelmannTamara RothenburgerSebastian MohrSebastian ScheichFederico ComoglioAnne WilkePhilipp StröbelHubert ServeMartin MichaelisNerea FerreirósGerd GeisslingerYong XiongOliver T. KepplerJindrich CinatlNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Thomas Oellerich Constanze Schneider Dominique Thomas Kirsten M. Knecht Olga Buzovetsky Lars Kaderali Christoph Schliemann Hanibal Bohnenberger Linus Angenendt Wolfgang Hartmann Eva Wardelmann Tamara Rothenburger Sebastian Mohr Sebastian Scheich Federico Comoglio Anne Wilke Philipp Ströbel Hubert Serve Martin Michaelis Nerea Ferreirós Gerd Geisslinger Yong Xiong Oliver T. Keppler Jindrich Cinatl Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
description	In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a potential biomarker and therapeutic target
format	article
author	Thomas Oellerich Constanze Schneider Dominique Thomas Kirsten M. Knecht Olga Buzovetsky Lars Kaderali Christoph Schliemann Hanibal Bohnenberger Linus Angenendt Wolfgang Hartmann Eva Wardelmann Tamara Rothenburger Sebastian Mohr Sebastian Scheich Federico Comoglio Anne Wilke Philipp Ströbel Hubert Serve Martin Michaelis Nerea Ferreirós Gerd Geisslinger Yong Xiong Oliver T. Keppler Jindrich Cinatl
author_facet	Thomas Oellerich Constanze Schneider Dominique Thomas Kirsten M. Knecht Olga Buzovetsky Lars Kaderali Christoph Schliemann Hanibal Bohnenberger Linus Angenendt Wolfgang Hartmann Eva Wardelmann Tamara Rothenburger Sebastian Mohr Sebastian Scheich Federico Comoglio Anne Wilke Philipp Ströbel Hubert Serve Martin Michaelis Nerea Ferreirós Gerd Geisslinger Yong Xiong Oliver T. Keppler Jindrich Cinatl
author_sort	Thomas Oellerich
title	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
title_short	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
title_full	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
title_fullStr	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
title_full_unstemmed	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
title_sort	selective inactivation of hypomethylating agents by samhd1 provides a rationale for therapeutic stratification in aml
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/95a48b4cc3c74d05b739c67d702815e2
work_keys_str_mv	AT thomasoellerich selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT constanzeschneider selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT dominiquethomas selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT kirstenmknecht selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT olgabuzovetsky selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT larskaderali selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT christophschliemann selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT hanibalbohnenberger selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT linusangenendt selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT wolfganghartmann selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT evawardelmann selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT tamararothenburger selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT sebastianmohr selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT sebastianscheich selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT federicocomoglio selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT annewilke selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT philippstrobel selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT hubertserve selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT martinmichaelis selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT nereaferreiros selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT gerdgeisslinger selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT yongxiong selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT olivertkeppler selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml AT jindrichcinatl selectiveinactivationofhypomethylatingagentsbysamhd1providesarationalefortherapeuticstratificationinaml
_version_	1718386427430961152

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Ejemplares similares